Siemens Healthineers CMO Charles Cooper spoke to us about the firm’s Enhanced Liver Fibrosis blood test and how it can be used to assess the risk of nonalcoholic fatty liver disease (NAFLD) progression and liver-related events.
Click on the video below for the interview.